Zogenix, Inc. (ZGNX) News
Filter ZGNX News Items
ZGNX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ZGNX News Highlights
- ZGNX's 30 day story count now stands at 3.
- Over the past 14 days, the trend for ZGNX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- RARE, GENE and CNS are the most mentioned tickers in articles about ZGNX.
Latest ZGNX News From Around the Web
Below are the latest news stories about Zogenix Inc that investors may wish to consider to help them evaluate ZGNX as an investment opportunity.
Analysts Expect Breakeven For Zogenix, Inc. (NASDAQ:ZGNX) Before LongWe feel now is a pretty good time to analyse Zogenix, Inc.'s ( NASDAQ:ZGNX ) business as it appears the company may be... |
Zogenix to Participate in the 20th Annual Needham Virtual Healthcare ConferenceEMERYVILLE, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, Executive Vice President, Chief Financial Officer, and Treasurer, will participate in a fireside chat on Monday, April 12, 2021, at the 20th Annual Needham Virtual Healthcare Conference. Zogenix Presentation DetailsDate: Monday, April 12, 2021Time: 11:00 AM Eastern Time The presentation will be webcast live and archived for 90 days on Zogenix's Investor Relations website at https://zogenixinc.gcs-web.com. About ZogenixZogenix is a global biopharmaceutical company committed to developing and commercializing therapies wit... |
Zogenix to Participate in the Stifel 3rd Annual CNS DayEMERYVILLE, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, Executive Vice President, Chief Financial Officer, and Treasurer, will participate in a fireside chat on Wednesday, March 31, 2021, at the Stifel 3rd Annual CNS Day. Zogenix Presentation DetailsDate: Wednesday, March 31, 2021Time: 2:30 PM Eastern Time The presentation will be webcast live and archived for 90 days on Zogenix's Investor Relations website at https://zogenixinc.gcs-web.com. About ZogenixZogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to ... |
Billionaire Jim Simons Snaps Up These 2 Biotech StocksQuant trading guru Jim Simons is calling it a day, sort of. The mathematician and cryptologist is famous in the investing community for bringing his analytical eye to the world of the stock exchange, creating both the quant trading revolution and a personal fortune now estimated at more than $22 billion. His has been a career of multifaceted success, and his innovations on Wall Street have influenced the strategies of two successive generations of traders. Simons has stepped down as Chairman of Renaissance Technologies ahead of his 83th birthday next month. However, Simons remains involved as a board member. |
Leerink Partners Stick to Their Buy Rating for Zogenix By Investing.comLeerink Partners Stick to Their Buy Rating for Zogenix |
Zogenix to Participate in the Raymond James Institutional Investors ConferenceEMERYVILLE, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Michael Smith, Executive Vice President, Chief Financial Officer, and Treasurer, will present a corporate overview and participate in a fireside chat on Wednesday, March 3, 2021, at the Raymond James Institutional Investors Conference. Zogenix Presentation DetailsDate:Wednesday, March 3, 2021Time: 3:50 PM Eastern Time The presentation will be webcast live and archived for 90 days on Zogenix's Investor Relations website at https://zogenixinc.gcs-web.com. About ZogenixZogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the ... |
Zogenix (NASDAQ:ZGNX) Announces Quarterly Earnings ResultsZogenix (NASDAQ:ZGNX) announced its earnings results on Thursday. The company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($0.21), MarketWatch Earnings reports. Zogenix had a negative return on equity of 53.91% and a negative net margin of 8,758.48%. ZGNX stock traded down $0.92 on Friday, hitting $21.24. 35,401 […] |
Zogenix to Participate in the 10th Annual SVB Leerink Global Healthcare ConferenceEMERYVILLE, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., will participate in a fireside chat on Friday, February 26, 2021, at the 10th Annual SVB Leerink Global Healthcare Conference. Zogenix Fireside Chat DetailsDate:Friday, February 26, 2021Time:1:00 PM Eastern Time The fireside chat will be webcast live and archived for 90 days on Zogenix's Investor Relations website at https://zogenixinc.gcs-web.com. About ZogenixZogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company’s first rare disease therapy... |
15 Best Micro-Cap Stocks to Buy NowIn this article, we will discuss the 15 Best Micro-Cap Stocks to Buy Now. You can skip our discussion of the merits of investing in micro-cap stocks and go directly to 5 Best Micro-Cap Stocks to Buy Now. A micro-cap stock has a market capitalization between $50 million to $1 billion. Micro-cap stocks have higher […] |
GW Pharma Soars To Record High On Jazz's $7.2 Billion Takeover DealJazz Pharmaceuticals agreed to buy GW Pharmaceuticals for $7.2 billion on Wednesday — sending GWPH stock to a record high. The deal values GWPH stock at a wealthy premium. |